Researchers are interested in studying how targeting the NF-κB pathway can improve cancer therapy options, whether it is through inhibiting the pathway to mediate other inflammatory pathways, repurposing pharmaceutical options that are already available on the market, combining therapies to enhance the efficacy of certain drugs, or exploring alternative plant-based therapies. Here, NFKB1 is linked to cancer.